Quick Answer
ALX ONCOLOGY HOLDINGS INC reported Diluted EPS of $1.90 per share (loss) for fiscal year 2025.
ALX ONCOLOGY HOLDINGS INC Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.90 | +26.4% |
| 2024 | -$2.58 | +31.0% |
| 2023 | -$3.74 | -23.4% |
| 2022 | -$3.03 | -46.4% |
| 2021 | -$2.07 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.41 | +29.3% | +16.3% |
| June 30, 2025 | -$0.49 | +35.5% | +15.5% |
| March 31, 2025 | -$0.58 | +18.3% | +0.0% |
| September 30, 2024 | -$0.58 | +53.2% | +23.7% |
| June 30, 2024 | -$0.76 | +9.5% | -7.0% |
| March 31, 2024 | -$0.71 | +4.1% | +42.7% |
| September 30, 2023 | -$1.24 | -42.5% | -47.6% |
| June 30, 2023 | -$0.84 | -3.7% | -13.5% |
- ALX ONCOLOGY HOLDINGS INC showed an increase of +26.4% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, ALX ONCOLOGY HOLDINGS INC’s diluted eps has grown by 8.2% (from $2.07 per share (loss) to $1.90 per share (loss)).
- The most recent figure is from ALX ONCOLOGY HOLDINGS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: